ArticleBreast cancer (Dove Medical Press)2023

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers.

Rayan Dakroub et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.